Fairmount Healthcare Fund II L.P.
SEC CIK 1769651 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | 10% | 2.90M | — | — | 1 | 2026-02-09 | 2026-02-09 |
| JBIO | Jade Biosciences, Inc. | Dir, 10% | 1.90M | — | — | 1 | 2025-10-06 | 2025-10-06 |
| VRDN | Viridian Therapeutics, Inc.\DE | Dir, 10%, See Remarks | 3.45M | $40.00M | — | 3 | 2024-01-22 | 2024-09-13 |
| SYRE | Spyre Therapeutics, Inc. | Dir, 10% | 0 | — | — | 1 | 2023-12-29 | 2023-12-29 |
Most active insiders at DMRA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schambye Hans T. | CEO, Dir | — | $15.0K |
| 2 | Winslow Garrett | GC | — | $12.8K |
| 3 | Firmani Lori | CFO | — | $2,890 |
| 4 | Sattarzadeh Sherwin | COO | — | — |
| 5 | Bruno Julianne | Dir | — | — |
| 6 | Hewes L. Becker | Chief Medical Off | — | — |
| 7 | Fairmount Healthcare Fund II L.P. | 10% | — | — |
| 8 | Jarrett Jennifer | See Remarks, Dir | — | — |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-02-12 | 2026-02-09 | DMRA | Damora Therapeutics, Inc. | Fairmount Healthcare Fund II L.P. | 10% | M - OptEx | $0.00 | +8.71M | 2.90M | New | $0 |
| DI | 2025-10-08 | 2025-10-06 | JBIO | Jade Biosciences, Inc. | Fairmount Healthcare Fund II L.P. | Dir, 10% | A - Grant | $9.14 | +1.33M | 1.90M | +236% | +$12.18M |
| I | 2024-09-17 | 2024-09-13 | VRDN | Viridian Therapeutics, Inc.\DE | Fairmount Healthcare Fund II L.P. | Dir, 10% | P - Purchase | $18.75 | +1.60M | 3.45M | +87% | +$30.00M |
| DMI | 2024-04-01 | 2024-03-28 | VRDN | Viridian Therapeutics, Inc.\DE | Fairmount Healthcare Fund II L.P. | Dir, 10% | J - Other | — | 0 | 1.85M | New | — |
| I | 2024-01-24 | 2024-01-22 | VRDN | Viridian Therapeutics, Inc.\DE | Fairmount Healthcare Fund II L.P. | Dir, 10%, See Remarks | P - Purchase | $21.00 | +476.2K | 1.84M | +35% | +$10.00M |
| MTI | 2023-12-29 | 2023-12-29 | SYRE | Spyre Therapeutics, Inc. | Fairmount Healthcare Fund II L.P. | Dir, 10% | J - Other | $0.00 | -2.62M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations